MVM Life Science Partners
Overview
MVM Life Science Partners LLP, founded in 1997, is a venture capital firm which manages three funds totaling more than $500 million and invests in companies that discover, develop and commercialize innovations in biotechnology, pharmaceuticals and medical devices for the life science and healthcare markets. MVM has offices in both London and Boston, making investments predominantly in Western Europe and the United States, and has a growing team with wide-ranging experience across the life science and private equity markets.
Investment Focus
- High growth potential
- Differentiated technology
- Address significant unmet needs
- Large addressable markets
- Durable protection against competition
Portfolio Companies
Reach MVM Life Science Partners directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about MVM Life Science Partners
What sectors does MVM Life Science Partners invest in?
MVM Life Science Partners invests in Healthcare Services, Digital Health, Pharmaceuticals, Medical Devices, Diagnostics and Biotechnology, and is based in Greater London, United Kingdom. MVM Life Science Partners is listed as a vc in the ConnectSafely investor database.
What stage does MVM Life Science Partners invest at?
MVM Life Science Partners backs companies at Seed, Early Stage, Series A, Series B, Growth and Late Stage, writing cheques of 20M - 100M.
Which regions does MVM Life Science Partners invest in?
MVM Life Science Partners invests across United States, United Kingdom, Canada, Germany, Japan and Australia.
What companies has MVM Life Science Partners invested in?
MVM Life Science Partners's portfolio includes Momenta, Domantis, Heptares, Preglem, Vascular Pathways, Beacon Endoscopic, Cara Therapeutics and Aegerion.
Last updated · Source: ConnectSafely investor database
